Nippon Chemiphar Co., Ltd.
Research Nippon Chemiphar Co., Ltd. (4539.T) on Bullrun: market cap JPY 5.66B, dividend yield 3.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4539.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyJPY
- Market capJPY 5.66B
- Dividend yield3.2%
- Financial periodFY2026
- RevenueJPY 33.09B
- Revenue growth1.6%
- Net incomeJPY 198.00M
- Free cash flow-JPY 329.00M
- Gross margin25.4%
Valuation Snapshot
latest market cap is JPY 5.66B; dividend yield is 3.2%.
Peer valuation comparison
Latest dividend yield is 3.23% versus a Healthcare sector median of 2.41% (34.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 33.09B | JPY 198.00M | -JPY 329.00M | 25.4% | 54.81 | JPY 5.34B | JPY 16.58B | JPY 19.51B |
| FY2025 | JPY 32.57B | JPY 294.00M | -JPY 2.12B | 26.9% | 81.72 | JPY 7.02B | JPY 18.06B | JPY 19.17B |
| FY2024 | JPY 30.75B | -JPY 180.00M | -JPY 2.34B | 25.2% | -50.14 | JPY 9.20B | JPY 16.98B | JPY 18.46B |
| FY2023 | JPY 31.56B | JPY 339.00M | -JPY 1.93B | 25.9% | 94.07 | JPY 10.53B | JPY 15.23B | JPY 18.53B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 5.66B | n/a | 3.2% | 50 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 50 JPY, yield 3.2%.
| Year | Dividends/share |
|---|---|
| FY2026 | 50 JPY |
| FY2025 | 50 JPY |
| FY2024 | 50 JPY |
| FY2023 | 50 JPY |
| FY2022 | 50 JPY |
About Nippon Chemiphar Co., Ltd.
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nippon Chemiphar Co., Ltd.'s market cap?
Nippon Chemiphar Co., Ltd.'s market capitalization is JPY 5.66B.
Does Nippon Chemiphar Co., Ltd. pay a dividend?
Nippon Chemiphar Co., Ltd. has a dividend yield of 3.2%.
What does Nippon Chemiphar Co., Ltd. do?
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements.